StreetAlpha.app
Home › Stocks › ZURA

Zura Bio Ltd (ZURA)

Healthcare
$1.03
▼ −4.17%
LAST CLOSE · NOV 17

Zura Bio develops antibody medicines for autoimmune and inflammatory diseases, and has no approved products yet. It last closed at $1.03 on Nov 17, down 4.17% on the day. The average 12-month price target from 3 analysts is $7.67 (+640.7% from the last close), with a high of $10.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $114K, the largest $114K.

AI Auto Pilots
Is ZURA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$93.5M
EPS (diluted)
−$1.11
Free cash flow
−$64.9M
Valuation
Market cap
$99.7M
96.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$187.7M
At Sep 30
Shares outstanding
96.3M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$25.7M−$25.7MFY2022FY2023: −$60.4M−$60.4MFY2023FY2024: −$52.4M−$52.4MFY2024FY2025: −$68.7M−$68.7MFY2025

From ZURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ZURA in the past 90 days
Average 12-month target
$7.67
▲ 640.7% upside

Based on 3 analysts who set a price target on ZURA in the past 90 days. The average target is $7.67, with a high of $10.00 and a low of $5.00, compared with the last close of $1.03.

Low $5.00Avg $7.67High $10.00
Blue marker: last close $1.03
Highest target$10.00
Average target$7.67
Lowest target$5.00
Latest rating changes
OppenheimerMaintained
Nov 10Buy$5
GuggenheimTarget lowered
Nov 10Buy$20 → $8
WedbushTarget lowered
Nov 9Buy$22 → $10
WedbushTarget raised
Aug 12Buy$15 → $22
GuggenheimMaintained
Aug 12Buy$20
DateFirmActionRatingPrice target
Nov 10OppenheimerMaintainedBuy$5
Nov 10GuggenheimTarget loweredBuy$20 → $8
Nov 9WedbushTarget loweredBuy$22 → $10
Aug 12WedbushTarget raisedBuy$15 → $22
Aug 12GuggenheimMaintainedBuy$20
Loading…

Technical Analysis

ZURA · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 188% below its 20 day and 268% below its 50 day average. It is 386% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $1.03, and the nearest resistance the Pivot R1 at $1.08.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 45.0%/day
Key levels
$7.4452 week high+622.3%
$5.03200 day average+388.3%
$4.70100 day average+356.3%
$3.86Swing high (Jun 15)+274.8%
$3.8150 day average+269.9%
$2.9820 day average+189.3%
$1.08Pivot R1+4.9%
$1.03Pivot+0.0%
$1.03Last close
$0.99Pivot S1−3.9%
$0.9352 week low−9.7%
$0.93Swing low (Nov 9)−9.7%
Indicators
RSI (14)24.94Oversold below 30Oversold
MACD-0.83Below its signal lineBearish
Stochastic5.0Near the bottom of its rangeOversold
ADX (14)26.1Trending down
Williams %R-97.2Oversold below −80, overbought above −20Oversold
CCI (20)-106.1Oversold below −100, overbought above 100Oversold
Rate of change−74.1%Change over 10 sessionsBearish
ATR (14)$0.47Typical daily range, 45.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZURA

What happened before

See how ZURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ZURA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ZURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ZURA in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$114K
Largest print
$114K
Loading…

ZURA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲66 buying vs 42 selling
  • ▼Held by funds -3.8 pts
  • ▲Funds holding +27
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding12295+28.4%
In funds' top 10110.0%
Held by funds72.0%75.7%−3.8 pts
New / increased33 / 3326 / 32+13.8%
Reduced / sold out36 / 619 / 24−2.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZURA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZURA is in one of them and how their past ZURA trades turned out.

ZURA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZURA in an article yet. Here's the latest on the wider market.

About Zura Bio

Zura Bio is a biotechnology company based in La Jolla, California, that develops antibody medicines for people with autoimmune and inflammatory diseases. Its tibulizumab candidate is designed to block two immune signals, IL-17A and BAFF, within a single molecule. The company also has crebankitug and torudokimab, which target other immune pathways. Tibulizumab is in two Phase 2 trials, in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, and no Zura Bio medicine is yet approved for sale.

Headquarters
La Jolla, CA